Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps
Spinal muscular atrophy (SMA) is a recessive disorder caused by a mutation in the survival motor neuron 1 gene (SMN1); it affects 1 in 11 000 newborn infants. The most severe and most common form, type 1 SMA, is associated with early mortality in most cases and severe disability in survivors. Nusine...
Huvudupphovsmän: | Gidaro, T, Servais, L |
---|---|
Materialtyp: | Journal article |
Språk: | English |
Publicerad: |
Wiley
2018
|
Liknande verk
Liknande verk
-
Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen
av: Aragon-Gawinska, K, et al.
Publicerad: (2019) -
Nusinersen and spinal muscular atrophies: Where are we in 2020?
av: Satish V Khadilkar, et al.
Publicerad: (2020-01-01) -
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
av: Finkel, RS, et al.
Publicerad: (2017) -
Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
av: Tommaso Nuzzo, et al.
Publicerad: (2023-02-01) -
Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
av: Benjamin Stolte, et al.
Publicerad: (2018-10-01)